- Home
- LDP vs AUTL Comparison
LDP vs AUTL Comparison
Compare LDP & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDP
- AUTL
- Stock Information
- Founded
- LDP 2012
- AUTL 2014
- Country
- LDP United States
- AUTL United Kingdom
- Employees
- LDP N/A
- AUTL N/A
- Industry
- LDP Finance Companies
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LDP Finance
- AUTL Health Care
- Exchange
- LDP Nasdaq
- AUTL Nasdaq
- Market Cap
- LDP 599.3M
- AUTL 590.8M
- IPO Year
- LDP N/A
- AUTL 2018
- Fundamental
- Price
- LDP $20.86
- AUTL $2.17
- Analyst Decision
- LDP
- AUTL Strong Buy
- Analyst Count
- LDP 0
- AUTL 3
- Target Price
- LDP N/A
- AUTL $10.20
- AVG Volume (30 Days)
- LDP 102.5K
- AUTL 1.1M
- Earning Date
- LDP 01-01-0001
- AUTL 03-13-2025
- Dividend Yield
- LDP 7.91%
- AUTL N/A
- EPS Growth
- LDP N/A
- AUTL N/A
- EPS
- LDP N/A
- AUTL N/A
- Revenue
- LDP N/A
- AUTL $10,091,000.00
- Revenue This Year
- LDP N/A
- AUTL $851.83
- Revenue Next Year
- LDP N/A
- AUTL $224.65
- P/E Ratio
- LDP N/A
- AUTL N/A
- Revenue Growth
- LDP N/A
- AUTL 82.71
- 52 Week Low
- LDP $16.16
- AUTL $2.07
- 52 Week High
- LDP $20.30
- AUTL $7.37
- Technical
- Relative Strength Index (RSI)
- LDP 58.96
- AUTL 41.81
- Support Level
- LDP $20.11
- AUTL $2.11
- Resistance Level
- LDP $20.96
- AUTL $2.26
- Average True Range (ATR)
- LDP 0.21
- AUTL 0.12
- MACD
- LDP 0.06
- AUTL 0.01
- Stochastic Oscillator
- LDP 81.50
- AUTL 27.78
About LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.